Company Encyclopedia
View More
name
INKON Life
300143.SZ
INKON Life Technology Co., Ltd. focuses on building an ecological platform for chain of prevention / diagnosis / treatment / rehabilitation, providing medical services for tumors in China and internationally. It provides medical devices solution for radiotherapy, life support, image enhancement, and chronic disease treatment, as well as oncology medical services. The company was formerly known as Starmap Medicine and Technology Co., Ltd.
175.65 B
300143.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care FacilitiesIndustry
Industry Ranking3/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE6.06%C
    • Profit Margin7.09%B
    • Gross Margin27.43%C
  • Growth ScoreB
    • Revenue YoY5.91%C
    • Net Profit YoY34.63%B
    • Total Assets YoY64.97%A
    • Net Assets YoY77.77%A
  • Cash ScoreB
    • Cash Flow Margin1411.06%B
    • OCF YoY5.91%C
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreB
    • Gearing Ratio38.53%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    INKON Life: Peng Wenci resigns as director and general manager, Ma Anjie succeeds as general manager

    On June 18th, INKON Life announced that the company's director, general manager, and legal representative Peng Wen applied to resign from his positions due to personal reasons, and after resigning, he will no longer hold any position in the company. The company's deputy general manager Ma Anjie applied to resign from the position of deputy general manager due to work transfer reasons, and after leaving, he will serve as the general manager of the company. The company's board of directors agreed to appoint Ma Anjie as the general manager of the company, while also serving as the legal representative of the company

    Zhitong·
    SZ
    300143
    +1.20%
    Zhitong·
    SZ
    300143
    +1.20%

    INKON Life: Acquisition of Changsha Kexin completed the industrial and commercial change registration

    On May 30th, INKON Life announced that the transaction for the 51% equity stake in Changsha Kexin Oncology Hospital Co., Ltd., which was previously acquired for RMB 357 million in cash, has completed the industrial and commercial change registration procedures. This means that Changsha Kexin officially becomes a subsidiary of INKON Life and is included in the company's consolidated financial statements

    Zhitong·
    SZ
    300143
    +1.20%
    Zhitong·
    SZ
    300143
    +1.20%

    INKON Life released its first-quarter performance, with a net profit attributable to the parent company of 29.9927 million yuan, an increase of 14.36%

    INKON Life released its Q1 2025 performance report, with operating revenue of 409 million yuan, a year-on-year decrease of 1.73%. The net profit attributable to the parent company was 29.9927 million yuan, a year-on-year increase of 14.36%; the net profit excluding non-recurring gains and losses was 29.9653 million yuan, a year-on-year increase of 25.77%. The basic earnings per share were 0.0404 yuan

    Zhitong·
    SZ
    300143
    +1.20%
    Zhitong·
    SZ
    300143
    +1.20%

    Fangsheng Pharmaceutical: Hunan Kexin plans to sell 51% of its subsidiary hospital Changsha Kexin

    Fangsheng Pharmaceutical announced that Hunan Kexin decided to sell 51% of Changsha Kexin's equity to INKON Life for 357 million yuan, and will transfer 29% and 20% of the equity in installments based on performance commitments. Hunan Kexin plans to pay the sale proceeds in three installments through equity repurchase, with an expected repurchase amount of 154.6834 million yuan. Fangsheng still has 98.5 million yuan of unpaid capital contributions, and it is expected that the first installment of the repurchase can recover 87.6055 million yuan, covering 88.94% of the unpaid amount

    Zhitong·
    SH
    603998
    +0.35%
    SZ
    300143
    +1.20%
    Zhitong·
    SH
    603998
    +0.35%
    SZ
    300143
    +1.20%

    INKON Life: The company has basically formed a three-layer layout of AI + healthcare

    INKON Life stated in a conference call with institutional investors that the company has basically formed a three-tier layout of AI + healthcare, including INKON Brain, capability components, and intelligent interaction engine. This layout aims to reshape the entire chain of medical services through AI, focusing on creating an AI innovation application platform, and has launched five types of intelligent employees

    Zhitong·
    SZ
    300143
    +1.20%
    Zhitong·
    SZ
    300143
    +1.20%
    © 2025 Longbridge｜Disclaimer